Alteration in Timing of Plerixafor Administration
Information source: Emory University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Autologous Transplantation
Intervention: Plerixafor (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Emory University Official(s) and/or principal investigator(s): R. Donald Harvey, PharmD, FCCP, Principal Investigator, Affiliation: Emory University Winship Cancer Institute
Summary
Typically, the collection of blood cells for autologous stem cell transplant is done after
the drugs granulocyte colony-stimulating factor (G-CSF) and plerixafor have been given to
activate the bone marrow stem cells to produce a certain type of blood cell, called CD34+
cells. Currently, plerixafor is given in the evening, about 11 hours before apheresis
(removal of blood) begins the following morning. The purpose of this study is to test
whether plerixafor can instead be given 17 hours before apheresis. This timing would be more
convenient since plerixafor would be given during normal clinic hours, and so patients would
be within a clinic environment if any side effects develop.
The study will look for the activation of CD34+ cells in patients who receive plerixafor 17
hours before apheresis. We will follow the number of patients that achieve the target
numbers of CD34+ cells, and the total number of CD34+ cells collected. These will be
compared to the numbers in previous studies giving plerixafor 11 hours before apheresis.
We will also assess the safety of giving plerixafor 17 hours before apheresis.
Clinical Details
Official title: WCI1680-09: Evaluation of Alterations in Time of Administration of Plerixafor (Mozobil ®, AMD3100) in Combination With G-CSF on Safety and CD34+ Cell Mobilization
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Number of Patients Who Collected ≥ 6 x 10^6 CD34+ Cells by Day 5 (4 Apheresis Sessions) With Plerixafor Administration at 1500.
Secondary outcome: Number of Patients Who on Day 1 Collected > 10 x 10^6 CD34+ Cells/kg Following Plerixafor Dosing at 1500 Hrs
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Age 18-70 years
2. MM patients in first or second complete or partial remission
3. ECOG performance status of 0 or 1
4. Up to 3 prior treatment regimens
5. Meet all eligibility requirements for autologous transplant
6. Adequate marrow function defined as WBC >3,000; ANC >1,500/mm3 ; Platelets
>75,000/mm3
7. Adequate renal function defined as creatinine clearance > 30 mL/min by
Cockcroft-Gault
8. Adequate liver function defined as AST/ALT/Bilirubin < 2 times upper limit of normal
9. Able to provide informed consent
10. Women not pregnant and agree to use contraception
Exclusion Criteria:
1. High risk co-morbidities for acute treatment complications (e. g., symptomatic
coronary artery disease)
2. Brain metastases or carcinomatous meningitis
3. Previous treatment with high dose chemotherapy and autologous transplant.
4. Previous attempt to collect B-HPCs following mobilization with growth factors alone,
growth factors and chemotherapy, or plerixafor and growth factors.
5. Acute infection or unexplained fever >38°C
6. Weight > 175% of ideal body weight as defined by the Devine equation.
7. Experimental therapy within 4 weeks
8. Cytokine administration in the previous 14 days
Locations and Contacts
Emory University Winship Cancer Institute, Atlanta, Georgia 30322, United States
Additional Information
Starting date: June 2010
Last updated: November 19, 2013
|